NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Short Interest Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 62,431 shares, a decrease of 40.8% from the December 15th total of 105,433 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 305,911 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 305,911 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are short sold.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Institutional investors have recently bought and sold shares of the business. Susquehanna International Group LLP purchased a new position in shares of NeuroOne Medical Technologies in the third quarter valued at about $47,000. Virtu Financial LLC purchased a new position in NeuroOne Medical Technologies in the 3rd quarter worth approximately $88,000. Vanguard Group Inc. lifted its holdings in NeuroOne Medical Technologies by 31.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after purchasing an additional 375,639 shares in the last quarter. Focus Financial Network Inc. bought a new position in NeuroOne Medical Technologies in the 3rd quarter worth approximately $31,000. Finally, Sio Capital Management LLC purchased a new stake in NeuroOne Medical Technologies during the 2nd quarter valued at approximately $2,390,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Price Performance

Shares of NMTC stock traded up $0.03 during trading hours on Thursday, reaching $0.90. 29,397 shares of the company traded hands, compared to its average volume of 460,198. The firm has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.79. The company has a market cap of $45.37 million, a P/E ratio of -11.19 and a beta of 0.70. NeuroOne Medical Technologies has a 12-month low of $0.40 and a 12-month high of $1.39.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, December 16th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. The company had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $2.47 million. NeuroOne Medical Technologies had a negative net margin of 29.81% and a negative return on equity of 74.69%. During the same quarter last year, the business earned ($0.46) EPS.

Analysts Set New Price Targets

A number of research firms have weighed in on NMTC. Zacks Research raised NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Wall Street Zen raised shares of NeuroOne Medical Technologies to a “hold” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, NeuroOne Medical Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $2.23.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.